Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998–2004.

Figures & data

Table I.  Characteristics of the two dose groups.

	60 Gy	45 Gy
n =	46 patients	34 patients
Age	62 (mean)	69 (mean)
	38–77 (range)	45–83 (range)
Sex	52% females	62% females
	48% males	38% males
FEV1%	77 (mean)	70 (mean)
	51–112 (range)	40–129 (range)
Karnofsky	93.5 (mean)	85.6 (mean)
	75–100 (range)	70–100 (range)
PTV cm3	681 (mean)	746 (mean)
	324–1457 (range)	180–1616 (range)
Number of chemotherapy cycles	5.7 (mean)	5.5 (mean)
	3–7 (range)	3–6 (range)
T 1-3N0M0	7 patients	1 patient
T4N+M0	39 patients	33 patients
Percent given PCI	54%	56%

Figure 1.  Overall survival (%)

Figure 2.  Survival (%), divided in two dose-groups.

Figure 3.  Survival (%), comparison between PCI patients and Non-PCI patients.

Figure 4.  Survival (%), comparison between males and females.

Table II.  Cause of death in the two dose groups.

%	60 Gy	45 Gy
Distant metastases (Brain)	68 (44)	75 (33)
Local recurrence	12	13
Other disease	18	4
Unknown	3	8